Fovista

After the release of Ophthotech Corp (NASDAQ: OPHT)'s fourth-quarter results, Leerink weighed in on the possibility of a path forward for Fovista, the company's candidate for the treatment of wet age-related macular degeneration. The Disappointment The company announced disappointing...

Shares of Ophthotech Corp (NASDAQ: OPHT) tanked more than 80 percent on Monday after the company announced that the primary endpoint in two Phase 3 trials exploring its Fovista® therapy was not met. Fovista is Ophthotech's therapy intended to be administered in combination with an anti VEGF agent...

On September 30, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced Phase 2 results for rinucumab, with the drug not meeting the primary endpoint of the study. On December 12, Ophthotech Corp (NASDAQ: OPHT) announced Phase 3 results for Fovista, which also did not achieve the primary...

Opthotech Corp (NASDAQ: OPHT) shares plummeted 84.6 percent on Monday morning after the company reported negative results in its Phase III OPH1002 and OPH1003 studies. The two combination trials in wet age-related macular degeneration (AMD) failed to meet primary endpoints. “We found no...

Stock traders don’t need to be options experts to get profitable trading ideas from the options market. Lots of stock traders watch the options market every day. They may not be trading options, but they want to know what options traders are thinking. Benzinga Pro provides real-time alerts to...

Egalet Corp (NASDAQ: EGLT) and Ophthotech Corp (NASDAQ: OPHT) have catalysts coming up before the end of the year that can bring glory or spell doom for these companies. Upcoming Catalysts The former is awaiting FDA decision on ARYMO ER, its lead drug candidate, which is an abuse-deterrent...

Long-term investors know the key to success in the stock market is choosing the right stocks and remaining patient. However, some traders prefer more excitement. Here is a look at seven stocks and ETFs that could see major instant upside before the end of the year. 1. Opthotech Corp (NASDAQ: OPHT)...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced that the Phase 2 CAPELLA trial of Eylea co-formulated with an anti-PDGFR-beta antibody, runicumab, did not meet the primary endpoint. Baird’s Brian P. Skorney maintained a Neutral rating on the company, with a price target of $448. He...

Ophthotech Corp (NASDAQ: OPHT), a biopharmaceutical company that develops therapeutics for the treatment of eye diseases, saw its shares fall more than 13 percent Friday. The decline is attributed to an announcement by Regeneron Pharmaceuticals Inc (NASDAQ: REGN), a larger biopharmaceutical...

BTIG’s Ling Wang believes Ophthotech Corp (NASDAQ: OPHT)'s Fovista has the potential to “break through the therapeutic ceiling of current anti-VEGF therapies.” Wang initiated coverage of the company with a Buy rating and price target of $92. Key Catalysts “We view the...